Featured Research

from universities, journals, and other organizations

Rice Uses Buckyballs To Reinvent 'Antibiotic Of Last Resort'; New Drug Could Become First Targeted Antibiotic, New Defense Against Bioterrorism

Date:
April 18, 2003
Source:
Rice University
Summary:
Rice University chemists hope a new variant of vancomycin that contains buckyballs -- tiny cage-shaped molecules of pure carbon -- could become the world's first targeted antibiotic, creating a new line of defense against bioweapons like anthrax.

HOUSTON, April 17, 2003 -- Rice University chemists hope a new variant of vancomycin that contains buckyballs -- tiny cage-shaped molecules of pure carbon -- could become the world's first targeted antibiotic, creating a new line of defense against bioweapons like anthrax.

Vancomycin, which entered clinical service 40 years ago, is the antibiotic of last resort, given only when all others fail. Unfortunately, vancomycin-resistant strains of bacteria have appeared in recent years.

In an effort to reinvigorate vancomycin, researchers have created vancomycin conjugates -- pairs of vancomycin molecules joined by an intermediate molecule that acts as a bridge -- some of which have proven more effective at killing resistant bacteria.

Rice Chemistry Professor Lon Wilson decided to create a buckyball-vancomycin conjugate following years of work developing biochemical targeting mechanisms for buckyballs, spherical cages containing 60 carbon molecules. By linking antibodies to a buckyball with anticancer drugs attached to it, Wilson and two of his graduate students, Tatiana Zakharian and Jared Ashcroft, are creating targeted compounds that will bind only with certain cells, like those found in melanoma tumors, for example.

"Having the ability to target antibiotics to attack specific bacterial antigens opens the door for treatments that simply aren't available today," said Wilson. "For example, we believe it's feasible to create a C60-vancomycin conjugate that attaches to anthrax while it is still in the spore form."

Weaponized anthrax is delivered in spores, a dormant form in which the disease is encased in a rugged shell. Once the spore finds its way into a living host, it germinates and becomes active.

Wilson said vancomycin can attack anthrax only after it germinates. However, having the ability to affix the antibiotic to a spore could enable the drug to knock the disease out when it tries to emerge from hibernation, before it has a chance to spread throughout the body and release its toxins.

A postdoctoral fellow in Wilson's lab, Dr. Andrey Mirakyan, recently presented preliminary results of the work at this spring's American Chemical Society annual meeting and they expect to publish research findings soon.

This research was sponsored by the Welch Foundation.


Story Source:

The above story is based on materials provided by Rice University. Note: Materials may be edited for content and length.


Cite This Page:

Rice University. "Rice Uses Buckyballs To Reinvent 'Antibiotic Of Last Resort'; New Drug Could Become First Targeted Antibiotic, New Defense Against Bioterrorism." ScienceDaily. ScienceDaily, 18 April 2003. <www.sciencedaily.com/releases/2003/04/030418081522.htm>.
Rice University. (2003, April 18). Rice Uses Buckyballs To Reinvent 'Antibiotic Of Last Resort'; New Drug Could Become First Targeted Antibiotic, New Defense Against Bioterrorism. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2003/04/030418081522.htm
Rice University. "Rice Uses Buckyballs To Reinvent 'Antibiotic Of Last Resort'; New Drug Could Become First Targeted Antibiotic, New Defense Against Bioterrorism." ScienceDaily. www.sciencedaily.com/releases/2003/04/030418081522.htm (accessed July 30, 2014).

Share This




More Matter & Energy News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Britain Testing Driverless Cars on Roadways

Britain Testing Driverless Cars on Roadways

AP (July 30, 2014) British officials said on Wednesday that driverless cars will be tested on roads in as many as three cities in a trial program set to begin in January. Officials said the tests will last up to three years. (July 30) Video provided by AP
Powered by NewsLook.com
China's Drone King Says the Revolution Depends on Regulators

China's Drone King Says the Revolution Depends on Regulators

Reuters - Business Video Online (July 30, 2014) Comparing his current crop of drones to early personal computers, DJI founder Frank Wang says the industry is poised for a growth surge - assuming regulators in more markets clear it for takeoff. Jon Gordon reports. Video provided by Reuters
Powered by NewsLook.com
3Doodler Bring 3-D Printing to Your Hand

3Doodler Bring 3-D Printing to Your Hand

AP (July 30, 2014) 3-D printing is a cool technology, but it's not exactly a hands-on way to make things. Enter the 3Doodler: the pen that turns you into the 3-D printer. AP technology writer Peter Svensson takes a closer look. (July 30) Video provided by AP
Powered by NewsLook.com
Climate Change Could Cost Billions, According To White House

Climate Change Could Cost Billions, According To White House

Newsy (July 29, 2014) A report from the White House warns not curbing greenhouse gas emissions could cost the U.S. billions. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins